Immuron (IMRN) Asset Utilization Ratio (2018 - 2024)
Immuron's quarterly Asset Utilization Ratio came in at 643857203153.26 in Q4 2024, down 277739290037.79% year-on-year from N/an in Q1 2024, and down 277739290037.79% quarter-over-quarter from 231.82 in Q4 2023.
Immuron has reported Asset Utilization Ratio for 7 years, with the latest figure at 643857203153.26 in Q4 2024.
- For the quarter ending Q4 2024, Asset Utilization Ratio fell 277739290037.79% year-over-year to 643857203153.26; the trailing twelve-month figure through Dec 2024 stood at 643857203153.26 (down 277739290037.79% YoY), and the FY2025 full-year result was 1.41, up 557.39% from the prior year.
- Asset Utilization Ratio for Q4 2024 stood at 643857203153.26, down from 231.82 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 231.82 in Q4 2023, with the low at 643857203153.26 in Q4 2024.
- Average Asset Utilization Ratio over 5 years is 107309533768.42, with a median of 101.17 recorded in 2021.
- Year-over-year, Asset Utilization Ratio surged 150852.25% in 2021 and sank 277739290037.79% in 2024.
- Tracing IMRN's Asset Utilization Ratio over 5 years: stood at 0.07 in 2020, then surged by 150852.25% to 102.2 in 2021, then slipped by 2.02% to 100.14 in 2022, then surged by 131.49% to 231.82 in 2023, then slumped by 277739290037.79% to 643857203153.26 in 2024.
- The last three Asset Utilization Ratio figures came in at 643857203153.26 (Q4 2024), 231.82 (Q4 2023), and 108.5 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -643.86 Bn |
| Dec 31, 2023 | 231.82 |
| Jun 30, 2023 | 108.50 |
| Dec 31, 2022 | 100.14 |
| Dec 31, 2021 | 102.20 |
| Dec 31, 2020 | 0.07 |
| Dec 31, 2019 | 0.74 |
| Dec 31, 2018 | 0.16 |